Fusion Antibodies collaborates with QUB Led Project in Multi-Million Pound Funding Bid

On August 12, 2020 Fusion Antibodies reported that a Belfast-based bid led by Queens University Belfast (QUB), is the only bid from Northern Ireland to be selected for the next stage of the UK Research and Innovation’s Strength in Places Fund (SIPF) (Press release, Fusion Antibodies, AUG 12, 2020, View Source [SID1234563503]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Fusion Antibodies is one of the Northern Ireland Precision Biomarkers and Therapeutics Consortium (NIBT), which is behind the bid. The consortium brings together partners from industry and academia including; Almac Group, Sonrai Analytics, Proaxsis, Diaceutics, and Exploristics.
The aim of the Consortium is to build on Northern Ireland’s existing strengths in digital health and biosciences to develop new, more cost-effective targeted drugs and antibodies and new ways of diagnosing cancer and other conditions.
The SIPF long-term aim is to boost research and innovation capacity and secure highly skilled jobs to the region to enhance its competitiveness and prosperity, and we support this application from Northern Ireland’s life and health science sector.

Paul Kerr, CEO of Fusion Antibodies said:

"We are incredibly excited to be a member of the Northern Ireland Therapeutics Consortium. This alliance between Queens University and other industry bodies has been established to drive and support ambitious growth within our Life Sciences sector.

"The NIBT will drive collaboration and connectivity across business, academia and health organisations.

"Not only is this early-stage funding a major endorsement of our plans, it is also an opportunity for the consortium to boast Northern Ireland as the ideal environment for cutting-edge healthcare R&D and innovations, benefiting patient health and economic growth alike."
The bid is one of just 17 ambitious projects to receive early-stage funding to develop full-stage proposals.
Teams behind these projects will now submit their bids to UK Research and Innovation (UKRI), with four to eight of the strongest set to receive between £10m and £50m each to carry out projects designed to drive substantial economic growth.
UKRI Strength in Places Fund lead, David Sweeney, said:
"Strength in Places is a flagship fund for UKRI. We welcome the focus of the UK Government’s R&D Roadmap in unlocking economic opportunities around local economy in more places around the UK.
"I am delighted with the range of bids funded across the UK in the second wave of Strength in Places that will foster the local ecosystems to support innovation and sustained growth and strengthen collaboration between industry and our world-class research base."

Precision Pathology Services and bioAffinity Technologies Announce Initiation of CLIA Validation for Non-Invasive Early Lung Cancer Test

On August 12, 2020 bioAffinity Technologies, a privately held biotech company advancing cutting-edge cancer diagnostics, and Precision Pathology Services, a CAP/CLIA-certified anatomic and clinical pathology laboratory, reported initiation of CLIA validation for CyPath Lung, a non-invasive flow cytometric test for early-stage lung cancer (Press release, BioAffinity Technologies, AUG 12, 2020, View Source [SID1234563538]). Precision Pathology has licensed bioAffinity’s intellectual property for development of CyPath Lung as a laboratory developed test (LDT).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"With our development phase complete, we are very pleased to start the validation studies for certification of the CyPath Lung flow cytometry test as an LDT," said Roby Joyce, MD, President of Precision Pathology. "This is a very exciting time for us. Lung cancer is the leading cancer killer. Our test for early detection of this dreaded disease can help many people live longer and healthier lives."

The validation study is conducted in accordance with College of American Pathologists (CAP) guidelines and Clinical Laboratory Improvement Amendments (CLIA) regulations. The CAP/CLIA validation study is designed to establish and validate performance characteristics of CyPath Lung, including accuracy, precision, reproducibility and analytical sensitivity, that are necessary for commercialization. Following CyPath Lung certification as an LDT, physicians can order the test for their patients at high risk for lung cancer who receive a positive screening result or are otherwise suspected of having the disease.

"Precision Pathology rightfully enjoys an excellent reputation for quick turnaround times while providing accurate pathology diagnoses. The company is known for its exceptionally responsive and helpful service to the physicians and patients it serves," bioAffinity President Maria Zannes said. "Dr. Joyce and his team will bring the same very high quality to CAP/CLIA validation of CyPath Lung and its eventual sale later this year. CyPath Lung is in excellent hands."

CyPath Lung is a flow cytometric test to aid in the diagnosis of lung cancer. Patients collect sputum samples non-invasively at home, a particular benefit during the COVID-19 pandemic. The sample is shipped overnight to the laboratory for processing. Sample data is acquired by flow cytometry, a technique that can count, sort and profile individual cells with remarkable speed. Using an automated analysis with pre-set parameters, CyPath Lung profiles the lung environment including the presence of cancer-associated cells. Data acquisition and physician reports can be generated in minutes.

In a recent CyPath Lung test validation trial of 150 individuals at high risk for lung cancer including 28 people with diagnosed cancer, the test showed 88% specificity and 82% sensitivity, a positive predictive value of 62% and a negative predictive value of 95%. The test was 87% specific and 92% sensitive in detecting cancer in participants who had nodules of less than 20 mm in diameter, indicating CyPath Lung is highly accurate in finding lung cancer in its earliest stages.

The U.S. Preventive Services Task Force recommends that smokers and former smokers at high risk for lung cancer undergo annual screening by low dose computed tomography (LDCT). Screening by LDCT has been proven to detect lung cancer at earlier stages when it can be more successfully treated. The National Lung Cancer Screening Trial (NLCST) of more than 53,000 participants resulted in a 20% decrease in lung cancer-specific mortality when LDCT screening was performed in high-risk patients. However, screening by LDCT had a low 3.8% positive predictive value (PPV) which raises the risk of unnecessary, invasive and costly procedures for those who test positive. In the NLCST, for every 100 people who received a positive LDCT, less than four of those individuals actually had lung cancer.

"CyPath Lung can assist physicians in determining next steps after a patient presents with a positive LDCT result, particularly in many cases where the lung nodule is considered indeterminate. In our test validation trial, bioAffinity successfully tested the automated analysis program used by CyPath Lung and found it to be fast and very robust in predicting who has cancer and who was at high risk but did not have lung cancer," Zannes said. "Physician reports can be generated immediately after flow cytometry acquires sample data in approximately 20 minutes per sample. Looking beyond lung cancer, we believe our automated platform can be successfully applied to cancer diagnostic tests for several other cancers, which will improve overall survival rates for patients through early diagnosis and treatment. We look forward to working with Precision Pathology in the development of additional life-saving diagnostic tests."

Personalis Announces Pricing of Public Offering of Common Stock

On August 12, 2020 Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for population sequencing and cancer, reported the pricing of its previously announced underwritten public offering of 6,578,947 shares of its common stock at a price to the public of $19.00 per share (Press release, Personalis, AUG 12, 2020, View Source [SID1234563452]). Gross proceeds to Personalis from the offering are expected to be $125 million, before deducting underwriting discounts and commissions and estimated offering expenses.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

In addition, the underwriters have been granted a 30-day option to purchase up to an additional 986,842 shares of common stock from a selling stockholder on the same terms and conditions. Personalis will not receive any proceeds from any sale of shares by the selling stockholder.

BofA Securities, Citigroup and Cowen are acting as joint book-running managers. BTIG, Needham & Company and Oppenheimer & Co. are acting as co-managers.

A shelf registration statement relating to the shares being sold in this offering was filed with the U.S. Securities and Exchange Commission on July 2, 2020, and was declared effective on July 10, 2020. A preliminary prospectus supplement and accompanying prospectus relating to the offering was filed with the SEC and are available for free on the SEC’s website located at View Source When available, electronic copies of the final prospectus supplement and accompanying prospectus relating to the offering may be obtained from BofA Securities, Inc., Attention: Prospectus Department, NC1‐004‐03‐43, 200 North College Street, 3rd floor, Charlotte, NC 28255‐0001, or by emailing [email protected]; Citigroup Global Markets Inc., c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, or by telephone at 1-800-831-9146; or Cowen and Company, LLC, c/o Broadridge Financial Solutions, Attention: Prospectus Department, 1155 Long Island Avenue, Edgewood, New York 11717, telephone: 631‐274‐2806.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

Celleron Therapeutics enters into a license agreement with Roche to improve the lives of patients living with tenosynovial giant cell tumour

On August 12, 2020 Celleron Therapeutics, the UK-based company developing novel medicines for cancer patients, reported the signing of a licensing agreement with Roche providing Celleron exclusive world-wide rights for the clinical development, manufacturing and commercialization of emactuzumab (Press release, Celleron, AUG 12, 2020, View Source [SID1234563471]). The closing is expected by end of 2020 after all conditions have been met.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

This license agreement of emactuzumab demonstrates Celleron’s commitment to cancer medicine development and its transformational potential for patients inflicted with cancer. Emactuzumab is a monoclonal antibody designed to target and deplete macrophages in the tumor tissue. It has shown a favourable safety profile in patients and very encouraging efficacy for diffuse tenosynovial giant cell tumour (TGCT), a rare disease characterised by the proliferation of macrophages in the synovial tissue in the joint and tendon sheath.

Professor Nick La Thangue, Chief Executive Officer of Celleron Therapeutics, commented: "We are very excited to be working on emactuzumab. Celleron’s commitment to developing transformative and novel therapies will ultimately allow emactuzumab to be brought to patients suffering from TGCT, which remains a very debilitating disease with limited clinical options."

Helix BioPharma Corp. and Moffitt Cancer Center Extend Immunotherapy Collaboration

On August 12, 2020O Helix BioPharma Corp. (TSX: HBP) ("Helix" or the "Company"), is a clinicalstage biopharmaceutical company developing unique therapies in the field of immuno-oncology for the prevention and treatment of cancer based on its proprietary technological platform DOS47, reported that it has extended its collaboration agreement with Moffitt Cancer Center ("Moffitt") for an additional year (Press release, Helix BioPharma, AUG 12, 2020, View Source [SID1234563505]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

To date, Helix and Moffitt have developed a new pancreatic adenocarcinoma mouse model suitable for testing the Company’s lead clinical compound L-DOS47 alone or in combination with immunotherapies. Preliminary data includes how L-DOS47 may work with immunotherapy were shown in American Association for Cancer Research (AACR) (Free AACR Whitepaper) ("AACR") Annual Meeting 2019. In addition, in September 2019, at the World Molecular Imaging Conference, the Company and Moffitt jointly presented a poster presentation on the pharmacodynamics of targeted urease and checkpoint blockade using Chemical Exchange Saturation Transfer ("CEST") and 31P-magnetic resonance spectroscopy ("31P-MRS"). The imaging technique is currently being used in the Company’s U.S. clinical study in advanced stage pancreatic patients.

In this next stage, the Company together with Moffit, intends to build on these early successes and provide additional preclinical support in using L-DOS47 with immunotherapies as clinical support.

"I look forward to expanding the use of L-DOS47 in combination with immunotherapy for future clinical application", said Dr. Heman Chao, Helix’s Chief Executive Officer